Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.55 |
| ▸ | SYK | P43405 | 3/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.49 |
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | STAT6 | P42226 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510247 | 0.91 | JAK3 (0.54) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL2483387 | 0.90 | JAK3 (0.63) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL2697088 | 0.87 | SYK (0.54) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL2477060 | 0.87 | JAK3 (0.50) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL2478422 | 0.87 | JAK3 (0.50) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL2478420 | 0.87 | JAK3 (0.50) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL2697667 | 0.87 | JAK3 (0.72) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL2485542 | 0.87 | STAT6 (0.55) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL12301697 | 0.86 | JAK3 (0.55) | JAK3SYKIRAK4JAK2JAK1 | |
| SCHEMBL12301693 | 0.86 | JAK3 (0.56) | JAK3SYKIRAK4JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | JAK3 1/4885SYK 137/4885IRAK4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.